Technical Analysis for BMEA - Biomea Fusion, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.14% | |
| Down 3 Days in a Row | Weakness | 0.14% | |
| Oversold Stochastic | Weakness | 0.14% | |
| Doji - Bullish? | Reversal | -11.30% | |
| Wide Bands | Range Expansion | -11.30% | |
| Oversold Stochastic | Weakness | -11.30% | |
| NR7 | Range Contraction | -11.52% | |
| NR7-2 | Range Contraction | -11.52% | |
| Narrow Range Bar | Range Contraction | -11.52% | |
| Wide Bands | Range Expansion | -11.52% |
| Alert | Time |
|---|---|
| Up 5% | about 6 hours ago |
| 60 Minute Opening Range Breakout | about 6 hours ago |
| Up 3% | about 7 hours ago |
| Up 2% | about 7 hours ago |
| Down 2 % | about 7 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of MENIN, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was founded in 2017 and is based in Redwood City, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
T
TraderMike over 1 year ago
I found this on the "Calm After Storm" scan today (I also like the NR7 & Doji). These little biotechs are always interesting after having a big pop based on some good/promising news. The standard plan seems to be to immediately issue a secondary offering -- which BMEA did. So now I'm looking for it to climb back above that offering price of $30 and retest the March high.
View full discussion...
| Indicator | Value |
|---|---|
| 52 Week High | 22.74 |
| 52 Week Low | 3.61 |
| Average Volume | 808,590 |
| 200-Day Moving Average | 10.39 |
| 50-Day Moving Average | 9.53 |
| 20-Day Moving Average | 10.01 |
| 10-Day Moving Average | 8.45 |
| Average True Range | 0.79 |
| RSI (14) | 26.47 |
| ADX | 33.67 |
| +DI | 17.12 |
| -DI | 33.10 |
| Chandelier Exit (Long, 3 ATRs) | 10.47 |
| Chandelier Exit (Short, 3 ATRs) | 9.46 |
| Upper Bollinger Bands | 13.34 |
| Lower Bollinger Band | 6.68 |
| Percent B (%b) | 0.06 |
| BandWidth | 66.52 |
| MACD Line | -0.65 |
| MACD Signal Line | -0.24 |
| MACD Histogram | -0.4141 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.66 | ||||
| Resistance 3 (R3) | 8.83 | 8.48 | 8.40 | ||
| Resistance 2 (R2) | 8.48 | 8.08 | 8.39 | 8.31 | |
| Resistance 1 (R1) | 7.79 | 7.83 | 7.61 | 7.62 | 8.23 |
| Pivot Point | 7.43 | 7.43 | 7.34 | 7.35 | 7.43 |
| Support 1 (S1) | 6.74 | 7.03 | 6.56 | 6.57 | 5.96 |
| Support 2 (S2) | 6.39 | 6.78 | 6.30 | 5.88 | |
| Support 3 (S3) | 5.70 | 6.39 | 5.79 | ||
| Support 4 (S4) | 5.53 |
